Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Subjects With Myelofibrosis (REFINE)

X
Trial Profile

A Phase 2 Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Subjects With Myelofibrosis (REFINE)

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Navitoclax (Primary) ; Ruxolitinib (Primary)
  • Indications Myelofibrosis; Polycythaemia vera
  • Focus Therapeutic Use
  • Acronyms REFINE
  • Sponsors AbbVie; AbbVie Germany
  • Most Recent Events

    • 13 Dec 2022 Results(As of Feb 07, 2022: N = 32 of Cohort-3) investigating whether the type of Myelofibrosis correlated with clinical outcomes and responses suggestive of disease modification among JAKi treatment naive patients and risk presented at the 64th American Society of Hematology Annual Meeting and Exposition
    • 10 Dec 2022 Results (n=32) published in an AbbVie media release.
    • 10 Dec 2022 According to an AbbVie media release, exploratory analysis from Cohort 3 of the trial were presented in an oral presentation at the 64th American Society of Hematology Annual Meeting & Exposition (ASH).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top